A Phase 3 interventional study of Sildenafil and Placebo in Pulmonary Hypertension and Systolic Dysfunction, sponsored by Hanmi Pharmaceutical Company Limited. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-11-27.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing sildenafil in Hypertension, Pulmonary — 1 open to participants now, 1 under way, none of them phase 3. sildenafil · Hypertension, Pulmonary.
Among the 51 studies testing sildenafil in Hypertension, Pulmonary, this one is the 7th largest by planned enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2013, is one of 15 in phase 3, and was the 36th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →1 of the 51 studies testing sildenafil in Hypertension, Pulmonary is open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
By country, each count listing its studies:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 20 · Phase 4 13
First in 2002; this study’s year is marked. 2 started in 2013.
This study's planned enrollment of 144 is above the median of 35 across 649 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 30 across the 50 interventional studies. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 51 have an industry lead sponsor. The 10 most frequent:
Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Hanmi Pharmaceutical Company Limited has 1 study filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing sildenafil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the safety and clinical efficacy of HGP1207 (Sildenafil) in subjects with pulmonary hypertension associated with systolic heart failure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sildenafil 20 mg
Drug: Sildenafil
Placebo
Drug: Placebo
Oral sildenafil 20 mg TID for 12 weeks
Also known as: HGP1207, PAHTENSION chewable tablet
Oral placebo TID for 12 weeks
Change from baseline in 6-min-walk test distance
Time frame: at 12 weeks
Change from baseline in 6-min-walk test distance
Time frame: at 6 weeks
Change from baseline in systolic pulmonary arterial pressure (PAP)
Time frame: at 6 weeks and 12 weeks
Change from baseline in [NT pro-BNP]
Time frame: at 6 weeks and 12 weeks
Improvement in NYHA functional class
Time frame: at 6 weeks and 12 weeks
Quality of life (QoL) assessed by EuroQoL(EQ-5D-3L) and EQ visual analogue scales (VAS)
Time frame: at 6 weeks and 12 weeks
Delaying time to first occurrence of either cardiovascular events
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Sep 2013, a primary completion of Dec 2018 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Hanmi Pharmaceutical Company Limited →